← Back to patent-cliff list

CAS 100-58-3

Bromo(phenyl)magnesiumphenylmagnesium bromide

Codes: (I)101438-38-a, (IX)70353-1-a, (II)663167-2-a, Ioflupane (123I)-018, LPHE-004

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateBacterial and fungal infectionBetamethasone/Clotrimazole/Gentamicin SulfatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelCandidiasisClotrimazoleVulvovaginal candidiasisClotrimazoleAspergillus infectionClotrimazoleOtitis externaClotrimazolePruritusClotrimazolePityriasis versicolorClotrimazoleBiliary tract cancerTasurgratinibBile duct cancerTasurgratinibSolid tumourTasurgratinibCholangiocarcinomaTasurgratinibBreast cancerTasurgratinibHepatic function declineTasurgratinibLewy body dementiaIoflupane (123I)Diagnostic agentIoflupane (123I)ParkinsonismIoflupane (123I)Alzheimer's diseaseIoflupane (123I)Parkinson's diseaseIoflupane (123I)DementiaIoflupane (123I)晕动病L-Phencynonate HydrochlorideCerebral infarctionL-Phencynonate HydrochlorideVertigoL-Phencynonate Hydrochloride

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
Betamethasone/Clotrimazole/Gentamicin SulfateTier C — Watch / trade-
PaclitaxelTier B — Position early-
ClotrimazoleTier C — Watch / trade-
TasurgratinibTier C — Watch / trade-
Ioflupane (123I)Tier C — Watch / trade-
L-Phencynonate HydrochlorideTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.